Vir Biotechnology, Inc. (VIR) stock

VIRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 12/3021% below fair value

$9.96−2.16 (-17.82%)

Close on Nov 13, 2026Market cap $1.69BP/E –Yield –

Vir Biotechnology EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Vir Biotechnology's EV/EBITDA was 1.1× on Apr 28, 2023, against 4.1× a year earlier.

Period	Period end	Value	Change (pts)
2023	Apr 28, 2023	1.1×	+0.5
2022	Dec 30, 2022	0.6×	–

Parsed from the XBRL in Vir Biotechnology's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is VIR.

Revenue growth1696.0% · median 22.3%

Gross margin22.6% · median 86.5%

Operating margin-69.8% · median -6.8%

Net margin-61.0% · median -7.5%

Advertisement
300 × 250

See a number that looks wrong?